354 Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer. (September 2015) - Voss, M.; Gordon, M.S.; Mita, M.; Rini, B.; Makker, V.; Macarulla, T.; Smith, D.; Kwak, E.L.; Cervantes, A.; Puzanov, I.; Pili, R.; Wang, D.; et al.